|
市場調查報告書
氣喘治療的單株抗體
Monoclonal Antibodies in Asthma: The choice between life and breath?
|
本報告已在2011年07月19日停止出版。
罹患重度氣喘的病患僅佔整體氣喘病患的5% ，然而為了治療這些病患所需要的花費卻相當地龐大。 由於急診病患也相當多 ，其處理方式也引起許多人的爭議。
專門針對各市場區塊進行調查及分析的英國調查公司 Datamonitor Corporation（總公司: 倫敦），調查與分析氣喘治療的單株抗體，並有系統地出版綜合報告書 "Monoclonal Antibodies in Asthma: The choice between life and breath?" 。
此報告書主要彙整治療重度氣喘的單株抗體使用現狀、及未來氣喘治療市場的新製品動向等。此報告書的概略架構如下所示。
第1章 摘要
第2章 疾病分類與疾病學
- 氣喘是嚴重的全球健康問題
- 氣喘的病態生理學的特徵：Th2通路對氣喘病的重要性
- 氣喘是發炎性呼吸狀態的集合
- 副腎皮質類固醇與氣管擴張藥的使用是最一般的氣喘治療
第3章 單株抗體的氣喘治療使用
第4章 當今氣喘治療的單株抗體：Xolair
- 氣喘治療以IgE為目標的理由
- Xolair: 2015年前達到10億美金市場的可能性
- Xolair的認證之路
- Xolair品牌的擴大：擴張至非過敏性氣喘的機會
第5章 通路革新與新目標的可能性
- 以氣喘的基本媒介為目標
- 技術革新：推動市場成長的活體化mAbs
- 藉由有效率地獲取病患達到擴大市場的機會：處理臨床實驗
附錄
- 生物表圖
- 關於Dtamonitor
- 簡稱
- 圖表
- 數值資料
Abstract
Overview
Introduction
Although only 5% of asthma suffers have severe asthma, these patients account
for a disproportionately high percentage of healthcare spending, as
asthma-related hospitalizations and emergency room visits are two of the
costliest outcomes, which highlights the significant unmet need in this market.
Scope
- Evaluation of the market potential and dynamics of Xolair, currently the
only marketed respiratory monoclonal antibody
- Examination of the key mediators in asthma and the evidence supporting
their role
- Identification and evaluation of fifteen monoclonal antibodies currently
in preclinical or clinical development to treat asthma
- Assessment of drivers and resistors of using monoclonal antibodies in the
severe asthma market
Report Highlights
Xolair is set to dominate the respiratory monoclonal antibody market through
to 2010, and data from the TENOR study may help Genentech and Novartis to
further increase market penetration if a role for IgE in non-atopic asthma is
identified.
Th2 mediators are the target of most respiratory monoclonal antibody
programmes, of which IL-13 is generating the greatest interest, with one third
of programmes targeting this mediator.
Although there is a significant unmet need among severe asthma patients who
are non-responsive to corticosteroids, the price point of respiratory
monoclonal antibodies will limit penetration in cost-conscious Europe,
transforming the US into the dominant revenue-creation market.
Reasons to Purchase
- Evaluate the current state of the monoclonal antibodies market and the
market capture potential for these products in severe asthma
- Assess the key technological trends to capitalize on opportunities in the
respiratory monoclonal antibody sector
- Identify possible targets to focus monoclonal antibody design
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Infectious Diseases pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Introduction
- Scope and coverage of the Brief
- Key findings from this Brief
- CHAPTER 2 DISEASE CLASSIFICATION AND EPIDEMIOLOGY
- Asthma is a significant global health problem
- Characterising asthma pathophysiology: the role of the Th2 pathway in
asthma symptoms
- The Th2 pathway plays a central role in asthma
- A series of complex events underlie asthma symptoms
- A broad range of mediators are involved in asthma pathophysiology
- Asthma attacks are triggered by a wide variety of factors
- Asthma is a collection of inflammatory respiratory conditions
- Eosinophilic/mast cell asthma, and neutrophilic asthma
- Atopic vs. non-atopic asthma and how it ties in with early-onset vs.
late-onset asthma
- Characterizing asthma by symptom frequency and severity
- Characteristics of the severe asthma patient population
- Corticosteroids and bronchodilators are currently the most common asthma
treatments
- CHAPTER 3 USING MONOCLONAL ANTIBODIES TO TREAT ASTHMA
- The evolution of the whole mAbs sector into a $10 billion market
- Business model evolution
- Therapy area evolution
- Market potential for respiratory mAbs: the pros and cons with using mAbs
for asthma
- CHAPTER 4 CURRENT RESPIRATORY MONOCLONAL ANTIBODY TREATMENTS FOR ASTHMA:
XOLAIR
- What is the rationale behind targeting IgE in asthma?
- Xolair: a $1 billion market potential by 2015
- Xolair's path to approval: what do other mAbs need to demonstrate?
- Xolair label extension: opportunity in non-atopic asthma
- CHAPTER 5 PIPELINE INNOVATIONS AND POTENTIAL TARGETS
- Targeting mediators that underlie asthma symptoms
- The development of mAbs that target these mediators: the pipeline
- Pipeline evaluation: IL-13 set to drive interest
- Technology evolution: development of humanized and fully human mAbs set
to drive market growth
- Maximizing market potential by effective patient population capture:
addressing clinical trial design issues
- APPENDIX
- Bibliography
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor Healthcare's research and analysis methodologies
- Disclaimer
- List of Tables
- Table 1: Classification of asthma by symptom frequency and severity
- Table 2: Xolair has demonstrated a range of effects in clinical trials
- Table 3: Mediators thought to play a role in the aetiology of asthma
- Table 4: Asthma mAbs currently in development
- List of Figures
- Figure 1: Key mediators and cells playing a role in the
pathophysiology of asthma
- Figure 2: Eosinophilic/mast cell and neutrophilic pathways
- Figure 3: Characteristics of eosinophil positive and negative asthma
- Figure 4: Percentage of asthma population with early or late-onset
asthma
- Figure 5: Severe persistent asthma makes up approximately one fifth of
asthma incidence in Europe
- Figure 6: Categorizing patients with severe asthma
- Figure 7: Evolution of mAb developers towards fully-integrated status
- Figure 8: Respiratory represents only a small percentage of mAb sales
through to 2010
- Figure 9: mAbs and anticholinergics power market growth
- Figure 10: The pros and cons of using mAbs to treat asthma
- Figure 11: 74,000 patients treated with Xolair by 2010, 74% in US
market
- Figure 12: Non-atopic is currently a significant untapped market for
respiratory mAbs
- Figure 13: Timeframe of asthma mAb development, based on mAb target
|
